Table 6.

Concordance indexes for resected pancreatic cancer in training and validation cohorts and in sensitivity analyses for the training US cohort

Model modification/subgroup	Concordance index	95% confidence interval
Training cohort
The US, our nomogram	0.60	0.59–0.61
The US, model based on both T and N stages	0.56	0.56–0.57
Validation cohorts
Belgium, our nomogram	0.58	0.55–0.60
Belgium, model based on both T and N stages	0.54	0.52–0.56
The Netherlands, our nomogram	0.62	0.59–0.65
The Netherlands, model based on both T and N stages	0.56	0.54–0.59
Slovenia, our nomogram	0.58	0.51–0.65
Slovenia, model based on both T and N stages	0.52	0.47–0.57
Norway, our nomogram	0.63	0.55–0.71
Norway, model based on both T and N stages	0.61	0.54–0.68
Sensitivity analyses for the training US cohort
Replacement
Age group in place of continuous age	0.59	0.59–0.60
Metastatic lymph node number in place of N stage	0.60	0.59–0.61
Lymph node ratio in place of N stage	0.61	0.61–0.62
The 8th version of T stage in place of the original stage	0.61	0.60–0.61
The 8th version of N stage in place of the original stage	0.60	0.59–0.61
The 8th version of T & N stages in place of the original stages	0.61	0.60–0.62
Addition
Harvested lymph node added	0.60	0.60–0.61
Tumor size added	0.61	0.60–0.61
Harvested lymph node & tumor size added	0.61	0.60–0.62
Subgroup
Diagnosis after 2009	0.60	0.59–0.61
White ethnicity	0.60	0.59–0.61
Pancreas head	0.60	0.59–0.61
Pancreas body & tail	0.61	0.59–0.63

Concordance indexes in sensitivity analyses greater than that for the overall nomogram in the US are highlighted in italics